Literature DB >> 21270133

Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Manickavasagom Alkondon1, Edna F R Pereira, Howard M Eisenberg, Yasushi Kajii, Robert Schwarcz, Edson X Albuquerque.   

Abstract

In the mouse hippocampus normal levels of kynurenic acid (KYNA), a neuroactive metabolite synthesized in astrocytes primarily by kynurenine aminotransferase II (KAT II)-catalyzed transamination of L-kynurenine, maintain a degree of tonic inhibition of α7 nicotinic acetylcholine receptors (nAChRs). The present in vitro study was designed to test the hypothesis that α7 nAChR activity decreases when endogenous production of KYNA increases. Incubation (2-7 h) of rat hippocampal slices with kynurenine (200 μM) resulted in continuous de novo synthesis of KYNA. Kynurenine conversion to KYNA was significantly decreased by the KAT II inhibitor (S)-(-)-9-(4-aminopiperazine-1-yl)-8-fluoro-3-methyl-6-oxo-2,3,5,6-tetrahydro-4H-1-oxa-3a-azaphenalene-5carboxylic acid (BFF122) (100 μM) and was more effective in slices from postweaned than preweaned rats. Incubation of slices from postweaned rats with kynurenine inhibited α7 nAChRs and extrasynaptic N-methyl-D-aspartate receptors (NMDARs) on CA1 stratum radiatum interneurons. These effects were attenuated by BFF122 and mimicked by exogenously applied KYNA (200 μM). Exposure of human cerebral cortical slices to kynurenine also inhibited α7 nAChRs. The α7 nAChR sensitivity to KYNA is age-dependent, because neither endogenously produced nor exogenously applied KYNA inhibited α7 nAChRs in slices from preweaned rats. In these slices, kynurenine-derived KYNA also failed to inhibit extrasynaptic NMDARs, which could, however, be inhibited by exogenously applied KYNA. In slices from preweaned and postweaned rats, glutamatergic synaptic currents were not affected by endogenously produced KYNA, but were inhibited by exogenously applied KYNA. These results suggest that in the mature brain α7 nAChRs and extrasynaptic NMDARs are in close apposition to KYNA release sites and, thereby, readily accessible to inhibition by endogenously produced KYNA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270133      PMCID: PMC3101010          DOI: 10.1124/jpet.110.177386

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  Kynurenine metabolism in Alzheimer's disease.

Authors:  H Baran; K Jellinger; L Deecke
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

2.  Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.

Authors:  Michael T Sapko; Paolo Guidetti; Ping Yu; Danilo A Tagle; Roberto Pellicciari; Robert Schwarcz
Journal:  Exp Neurol       Date:  2005-08-15       Impact factor: 5.330

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

5.  Ric-3 promotes alpha7 nicotinic receptor assembly and trafficking through the ER subcompartment of dendrites.

Authors:  John K Alexander; Daphna Sagher; Arcadius V Krivoshein; Manuel Criado; Gregory Jefford; William N Green
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

6.  Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats.

Authors:  Trevor W Stone
Journal:  Eur J Neurosci       Date:  2007-04-25       Impact factor: 3.386

7.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 8.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

9.  Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels.

Authors:  M H Selina Mok; Anne-Cécile Fricker; Annette Weil; James N C Kew
Journal:  Neuropharmacology       Date:  2009-06-11       Impact factor: 5.250

Review 10.  Astrocytes, from brain glue to communication elements: the revolution continues.

Authors:  Andrea Volterra; Jacopo Meldolesi
Journal:  Nat Rev Neurosci       Date:  2005-08       Impact factor: 34.870

View more
  17 in total

1.  The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.

Authors:  Susanna Campesan; Edward W Green; Carlo Breda; Korrapati V Sathyasaikumar; Paul J Muchowski; Robert Schwarcz; Charalambos P Kyriacou; Flaviano Giorgini
Journal:  Curr Biol       Date:  2011-06-07       Impact factor: 10.834

2.  Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Eur J Neurosci       Date:  2012-04-20       Impact factor: 3.386

3.  Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Edson X Albuquerque
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

Review 4.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

5.  Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid.

Authors:  Jyotirmoy Banerjee; Manickavasagom Alkondon; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2012-02-17       Impact factor: 4.030

Review 6.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

7.  Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Authors:  Ikwunga Wonodi; Robert P McMahon; Nithin Krishna; Braxton D Mitchell; Judy Liu; Matthew Glassman; L Elliot Hong; James M Gold
Journal:  Schizophr Res       Date:  2014-11-14       Impact factor: 4.939

Review 8.  Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Authors:  Francesca M Notarangelo; Ana Pocivavsek
Journal:  Neuropharmacology       Date:  2016-03-02       Impact factor: 5.250

9.  Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.

Authors:  K S Alexander; A Pocivavsek; H-Q Wu; M L Pershing; R Schwarcz; J P Bruno
Journal:  Neuroscience       Date:  2013-02-06       Impact factor: 3.590

Review 10.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.